Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Raloxifene HCL, Evista, LY139481
Raloxifene · 3 trials · 5 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Raloxifene HCL 60 mg orally once a day |
| 2 | EXPERIMENTAL | Raloxifene HCL 120 mg orally once a day |
| 3 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| raloxifene | DRUG | - |
| placebo | DRUG | - |
| Raloxifene HCL | DRUG | Raloxifene HCL 60 mg orally once daily |
| medroxyprogesterone acetate | DRUG | - |
| estrogen | DRUG | - |
| 17 beta estradiol | DRUG | - |
Inclusion Criteria: * Postmenopausal women with established coronary heart disease or at risk for a major coronary event. Exclusion Criteria: * Postmenopausal symptoms that required estrogen replacement therapy. * Suspected or known history of breast or endometrial carcinoma. * Known or probable ...
Top 4 of 19 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| United Therapeutics Corporation | UTHR | 1 | PHASE3 | Ralinepag |
| Roivant Sciences Ltd. | ROIV | 3 | PHASE3 | Mosliciguat |
| Eli Lilly and Company | LLY | 1 | PHASE3 | Lepodisiran |
| Illumina, Inc. | ILMN | 1 | PHASE1 | 18F-mFBG for administration |
Raloxifene is used to treat postmenopausal osteoporosis. It has also been studied in postmenopausal women for cardiovascular disease, vasomotor symptoms such as hot flashes and night sweats, and breast neoplasms. It is a small molecule modulator of the estrogen receptors ESR1 and ESR2.
Raloxifene targets the estrogen receptors ESR1 and ESR2. It acts as a modulator of these receptors, which is why it is classified as a selective estrogen receptor modulator. This receptor activity underlies its use in postmenopausal osteoporosis and its study in cardiovascular and vasomotor conditions.
Raloxifene is developed by Eli Lilly and Company, which trades under the ticker LLY. Eli Lilly is the sponsor associated with the clinical development program for raloxifene, including the Phase 3 osteoporosis and cardiovascular outcomes trials.
Raloxifene has been studied in Phase 3 clinical development, including a Phase 3 osteoporosis trial and a Phase 3 cardiovascular outcomes trial. It is also listed as having completed Phase 2 work in vasomotor symptoms. The completed trials include NCT00670319, NCT00332553, and NCT00190593.
Raloxifene has been studied in NCT00670319, a Phase 3 comparison of raloxifene hydrochloride and placebo in postmenopausal women with osteoporosis enrolling 7,705 participants, NCT00190593, the Phase 3 Raloxifene Use for The Heart trial enrolling 10,000 women, and NCT00332553, a Phase 2 study of hot flashes and night sweats.
Yes, Raloxifene HCL refers to the hydrochloride salt form of raloxifene, the same active drug. The two names are used interchangeably, and the Phase 3 osteoporosis trial NCT00670319 is titled as a comparison of raloxifene hydrochloride and placebo.